Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34838156

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Jan
First author
Wen PY

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):3-4. doi: 10.1016/S1470-2045(21)00662-8.
    note
    Source null
    related pmid
    34838157
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Mar;23(3):e93. doi: 10.1016/S1470-2045(21)00754-3.
    note
    Source null
    related pmid
    35240094
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2022 Mar;23(3):e94. doi: 10.1016/S1470-2045(22)00076-6.
    note
    Source null
    related pmid
    35240095
    relationship
    Comment in

Authors and identifiers

  1. name
    Wen PY
    type
    Author
  2. name
    Stein A
    type
    Author
  3. name
    van den Bent M
    type
    Author
  4. name
    De Greve J
    type
    Author
  5. name
    Wick A
    type
    Author
  6. name
    de Vos FYFL
    type
    Author
  7. name
    von Bubnoff N
    type
    Author
  8. name
    van Linde ME
    type
    Author
  9. name
    Lai A
    type
    Author
  10. name
    Prager GW
    type
    Author
  11. name
    Campone M
    type
    Author
  12. name
    Fasolo A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wen PY
    type
    Author
  2. name
    Stein A
    type
    Author
  3. name
    van den Bent M
    type
    Author
  4. name
    De Greve J
    type
    Author
  5. name
    Wick A
    type
    Author
  6. name
    de Vos FYFL
    type
    Author
  7. name
    von Bubnoff N
    type
    Author
  8. name
    van Linde ME
    type
    Author
  9. name
    Lai A
    type
    Author
  10. name
    Prager GW
    type
    Author
  11. name
    Campone M
    type
    Author
  12. name
    Fasolo A
    type
    Author
bibliography ids
  1. nci-bib-c261763005dfc900d77fa21c
book metadata
content sha256
9698a208502d8abf8d53b3b2da7193e74436c31bacec7e92adad8762a72dd2b8
document type
citation
dois
  1. 10.1016/S1470-2045(21)00578-7
electronic publication date
display
2021 Nov 24
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34838156
immutable id
pubmed:34838156@9698a208502d8abf8d53b3b2da7193e74436c31bacec7e92adad8762a72dd2b8
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
53-64
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):3-4. doi: 10.1016/S1470-2045(21)00662-8.
    note
    Source null
    related pmid
    34838157
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Mar;23(3):e93. doi: 10.1016/S1470-2045(21)00754-3.
    note
    Source null
    related pmid
    35240094
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2022 Mar;23(3):e94. doi: 10.1016/S1470-2045(22)00076-6.
    note
    Source null
    related pmid
    35240095
    relationship
    Comment in
outcomes validated
false
pmid
34838156
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
482d33eb3574355cb3af1c565780bb12bc78a7b2721fcb5e84aa5bfec9b22772
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jan
precision
month
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, N.I.H., Extramural
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34838156/
title
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.

Preserved source evidence · Not medical advice